TP53 and colorectal carcinoma: Since our preliminary in vitro investigation showed the therapeutic potential of GLPG1790 also versus CRC [13], we decided to better characterize the pharmacological action of this drug on CRC by using in vitro and in vivo approaches on p53 wild-type or mutated CRC cell lines.